Current Treatment Options in Oncology最新文献_第10页

Extent of Resection and Outcomes of Patients with Primary Malignant Brain Tumors 原发性恶性脑肿瘤患者的切除范围和疗效

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-13 DOI: 10.1007/s11864-023-01158-0

Brandy Ndirangu, Kevon Bryan, Edjah Nduom

引用次数: 0

Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System 心脏肿瘤科并发高血压、舒张功能障碍、肺水肿或外周水肿综合征：病例研究、文献综述和新的分类系统

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-13 DOI: 10.1007/s11864-023-01141-9

Rebekah Summey, Rana Aliani, Lindsey A. McAlarnen, Nicole Sequeira, Tahseen Shaik, Denise Uyar, Sherry-Ann Brown

{"title":"Syndromes of Concurrent Hypertension, Diastolic Dysfunction, and Pulmonary or Peripheral Edema in Cardio-Oncology: Case Studies, Literature Review, and New Classification System","authors":"Rebekah Summey, Rana Aliani, Lindsey A. McAlarnen, Nicole Sequeira, Tahseen Shaik, Denise Uyar, Sherry-Ann Brown","doi":"10.1007/s11864-023-01141-9","DOIUrl":"https://doi.org/10.1007/s11864-023-01141-9","url":null,"abstract":"Individuals who have ever been diagnosed with cancer are at increased risk for cardiovascular conditions during and after cancer treatment. Especially during cancer treatment, cardiovascular conditions can manifest in many ways, including peripheral or pulmonary edema. Edema can indicate volume overload affecting the heart even without other unequivocal evidence of apparent diastolic or systolic left ventricular dysfunction, particularly at rest. We propose a novel algorithm to streamline the diagnostic evaluation and cardiovascular classification for cancer patients with edema. We initially advise prompt evaluation with a chest X-ray and echocardiogram. We then suggest classification into one of five categories based on the timing of presentation of edema relative to cancer treatment, as well as echocardiography results and the presence or absence of hypertension or lymphatic causes of edema. This classification tool can then be utilized to guide further cardiovascular management suggestions. These concurrent syndromes presenting as edema may indicate the development or aggravation of undiagnosed diastolic dysfunction with or without hypertension, even if transiently present only while on cancer treatment.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138628142","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Perioperative Immunotherapy in Non-Small Cell Lung Cancer 非小细胞肺癌围手术期免疫疗法

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-13 DOI: 10.1007/s11864-023-01160-6

Jenny O’Brien, J. Nicholas Bodor

{"title":"Perioperative Immunotherapy in Non-Small Cell Lung Cancer","authors":"Jenny O’Brien, J. Nicholas Bodor","doi":"10.1007/s11864-023-01160-6","DOIUrl":"https://doi.org/10.1007/s11864-023-01160-6","url":null,"abstract":"The standard of care in patients with early-stage non-small cell lung cancer (NSCLC) following surgical resection has been adjuvant chemotherapy for the last two decades, despite modest improvements in survival and high rates of disease recurrence. Numerous clinical trials have reported practice-changing findings demonstrating a benefit in disease-free survival (DFS) or event-free survival (EFS) with perioperative immunotherapy. This has led to several recent regulatory approvals supporting the use of adjuvant immunotherapy or neoadjuvant immuno-chemotherapy in NSCLC, and such therapies are now an integral component of care for early-stage disease. However, in select cases, such as in the presence of certain tumor oncogenes associated with immunotherapy resistance, the use of checkpoint inhibitors in the perioperative setting should generally be avoided. This speaks to the importance of integrating routine tissue-based molecular profiling, that evaluates for tumor oncogene mutations and PD-L1 expression, into our practice when caring for patients with early-stage NSCLC. While an overall survival (OS) advantage has yet to be firmly established from many of the recent studies evaluating perioperative immunotherapy, it is expected that an OS benefit and higher rates of cure will become evident as these data mature, especially among patients with greater levels of tumor PD-L1 expression.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138627877","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview 辅助与替代医学干预治疗胰腺癌的现状 - 概述

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-11 DOI: 10.1007/s11864-023-01146-4

Aleksandra Tarasiuk, Grzegorz Mirocha, Jakub Fichna

{"title":"Current status of Complementary and Alternative Medicine Interventions in the Management of Pancreatic Cancer – An Overview","authors":"Aleksandra Tarasiuk, Grzegorz Mirocha, Jakub Fichna","doi":"10.1007/s11864-023-01146-4","DOIUrl":"https://doi.org/10.1007/s11864-023-01146-4","url":null,"abstract":"Pancreatic cancer (PC) remains the deadliest cancer worldwide. Most patients are diagnosed at the advanced or metastatic stage, leading to a poor prognosis. Awareness of the limitations of current therapy and accompanying pain, depression, malnutrition, and side effects of chemoradiotherapy may lead patients and physicians towards complementary and alternative medicine (CAM). CAM refers to a diverse set of medical and healthcare practices, products, and systems that are not part of conventional Western medicine. Despite the low-quality evidence supporting the efficacy of these methods, they remain appealing due to patients' beliefs, fear of death, and the slow development of conventional therapy. Hence, the possibility of using natural products for pancreatic cancer is increasing. CAM options such as: medical cannabis, plants, fungi, herbal formulas, and injections, which originate primarily from traditional Chinese or Japanese medicine i.e. Curcuma longa, Panax ginseng, Poria cocos, Hochuekkito, Juzentaihoto, and Rikkunshito, Shi-quan-da-bu-tang/TJ-48, Huang-qin-tang, Shuangbai San, Wen Jing Zhi Tong Fang, Xiang-Sha-Liu-jun-zi-tang, Aidi injection, Brucea javanica oil emulsion/Yadanziyouru injection, Compound Kushen injection, Huachansu injection, Kangai injection and Kanglaite injections are becoming promising candidates for the management of pancreatic cancer. The abovementioned substances/medications are the most popular or potentially effective in PC treatment and consequently CAM-based adjuvant therapy through improving patients’ quality of life, might be a useful addition in the treatment of pancreatic cancer patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138567731","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer. 非小细胞肺癌表皮生长因子受体-TKIs心脏毒性的研究进展。

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-12-28 DOI: 10.1007/s11864-023-01150-8

Yinan Yu, Jianguo Zhao, Jiaona Xu, Rui Bai, Zewei Gu, Xialin Chen, Jianfang Wang, Xueying Jin, Gaoyang Gu

{"title":"Research Progress on the Cardiotoxicity of EGFR-TKIs in Non-Small Cell Lung Cancer.","authors":"Yinan Yu, Jianguo Zhao, Jiaona Xu, Rui Bai, Zewei Gu, Xialin Chen, Jianfang Wang, Xueying Jin, Gaoyang Gu","doi":"10.1007/s11864-023-01150-8","DOIUrl":"10.1007/s11864-023-01150-8","url":null,"abstract":"Opinion statement: With the development of molecular biology and histology techniques, targeted therapy for non-small cell lung cancer (NSCLC) has emerged, which is highly effective and has marginal side effects. Epidermal growth factor receptor (EGFR) was the first driver gene discovered, whose three generations of therapeutic use have its characteristics and benefits in clinical practice. However, cardiovascular complications by EGFR-tyrosine kinase inhibitors (EGFR-TKIs) in preclinical studies have been increasingly reported, including heart failure, cardiomyopathy, and QT prolongation, among others. Cardiotoxicity of targeted drugs significantly affects the therapeutic effect of NSCLC and has become the second leading cause of death in NSCLC. The aim of the present review was to recognize the potential cardiotoxicity of third-generation targeted drugs in the treatment of NSCLC and their associated mechanisms to help clinicians identify and prevent it early in the treatment, minimize the cardiotoxicity of targeted drugs, and improve the therapeutic effect of patients.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139049676","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Frontiers of Ovarian Carcinosarcoma. 卵巢癌肉瘤的前沿。

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-11-08 DOI: 10.1007/s11864-023-01138-4

Ayden Ismail, Sunyoung Choi, Stergios Boussios

{"title":"Frontiers of Ovarian Carcinosarcoma.","authors":"Ayden Ismail, Sunyoung Choi, Stergios Boussios","doi":"10.1007/s11864-023-01138-4","DOIUrl":"10.1007/s11864-023-01138-4","url":null,"abstract":"Opinion statement: Ovarian carcinosarcoma (OCS), also known as a malignant mixed Müllerian tumour (MMMT), is a rare and aggressive form of cancer that accounts for less than 5% of ovarian cancers. It is characterized by high morbidity and mortality rates, with a median overall survival (OS) of less than 2 years. Several factors, including advancing age, nulliparity, reduced lactation rates, decreased use of oral contraceptive pills, genetic mutations in BRCA (breast cancer) genes, and the use of assisted reproductive technology, may increase the risk of OCS. Poor prognostic factors include an advanced stage at diagnosis, older age, lymph node metastasis, suboptimal surgical cytoreduction, the presence of heterologous features on histopathology, and increased expression of vascular endothelial growth factor (VEGF), tumour protein p53, and p53 alongside Wilms tumour 1 (WT1). The main treatment approach for OCS is cytoreductive surgery followed by platinum-based chemotherapy, although immunotherapy is showing promise. Homologous recombination deficiency (HRD) testing may enhance outcomes by enabling personalized immunotherapy and targeted therapies for specific patient groups, thereby reducing unnecessary side effects and healthcare costs. However, there is currently a lack of standardised treatment regimens for OCS patients, with most studies consisting of case reports and a shortage of suitable comparator groups. This article aims to provide clinicians with information on the epidemiology, risk factors, prognostic factors, and latest therapeutic advancements in OCS.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781844/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488384","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Updates in Management of Malignant Pleural Mesothelioma. 恶性胸膜间皮瘤的治疗进展。

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-11-17 DOI: 10.1007/s11864-023-01148-2

Alexius John, Hazel O'Sullivan, Sanjay Popat

引用次数: 0

Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies. 慢性髓系白血病中酪氨酸激酶抑制剂的心血管不良事件:临床相关性、对预后的影响、预防措施和治疗策略

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-12-04 DOI: 10.1007/s11864-023-01149-1

Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Paolo Spallarossa, Francesco Passamonti

{"title":"Cardiovascular Adverse Events of Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: Clinical Relevance, Impact on Outcome, Preventive Measures and Treatment Strategies.","authors":"Alessandra Iurlo, Daniele Cattaneo, Cristina Bucelli, Paolo Spallarossa, Francesco Passamonti","doi":"10.1007/s11864-023-01149-1","DOIUrl":"10.1007/s11864-023-01149-1","url":null,"abstract":"Opinion statement: The introduction of TKIs into the therapeutic armamentarium of CML has changed the disease paradigm, increasing long-term survival from 20% to over 80%, with a life expectancy now approaching that of the general population. Although highly effective, TKIs also have a toxicity profile that is often mild to moderate, but sometimes severe, with multiple kinases involved in the development of adverse events (AEs). Among others, cardiovascular AEs observed in TKI-treated CML patients may represent a significant cause of morbidity and mortality, and their pathogenesis is still only partially understood. In view of the recent introduction into daily clinical practice of new TKIs, namely the STAMP inhibitor asciminib, with a distinct safety profile, hematologists now more than ever have the opportunity to select the most suitable TKI for each patient, an aspect that will be fundamental in terms of personalized preventive and therapeutic strategies. Furthermore, physicians should be aware of the feasibility of TKI dose modifications at all stages of the patients' treatment journey, both at diagnosis for frail or elderly subjects or with multiple comorbidities, and during follow-up for those patients who experience toxicity, as well as to prevent it, with the main objective of reducing side effects while maintaining the response. Consequently, preserving the cardiovascular health of CML patients will likely be a more urgent topic in the near future, with specific measures aimed at controlling cardiovascular risk factors through a multidisciplinary approach involving a panel of healthcare professionals together with the hematologist.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138479139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities. 工程树突状细胞疫苗在癌症免疫治疗中的应用:挑战与机遇。

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-11-14 DOI: 10.1007/s11864-023-01143-7

Ping Li, Linan Jia, Xiaobo Bian, Shutao Tan

{"title":"Application of Engineered Dendritic Cell Vaccines in Cancer Immunotherapy: Challenges and Opportunities.","authors":"Ping Li, Linan Jia, Xiaobo Bian, Shutao Tan","doi":"10.1007/s11864-023-01143-7","DOIUrl":"10.1007/s11864-023-01143-7","url":null,"abstract":"Opinion statement: The primary objective of this study is to evaluate the effectiveness of cancer vaccines containing genetically modified dendritic cells (DCs) in inducing transformational immune responses. This paper sheds considerable light on DCs' function in advancing treatment techniques. This objective is achieved by thoroughly analyzing the many facets of DCs and their strategic integration into cancer treatment. Due to their role as immune response regulators, DCs can potentially enhance cancer treatment strategies. DCs have the potential to revolutionize immunotherapy, as shown by a comprehensive analysis of their numerous characteristics. The review deftly transitions from examining the fundamentals of preclinical research to delving into the complexities of clinical implementation while acknowledging the inherent challenges in translating DC vaccine concepts into tangible progress. The analysis also emphasizes the potential synergistic outcomes that can be achieved by combining DC vaccines with established pharmaceuticals, thereby emphasizing the importance of employing a holistic approach to enhance treatment efficacy. Despite the existence of transformative opportunities, advancement is hindered by several obstacles. The exhaustive analysis of technical complexities, regulatory dynamics, and upcoming challenges provides valuable insights for overcoming obstacles requiring strategic navigation to incorporate DC vaccines successfully. This document provides a comprehensive analysis of the developments in DC-based immunotherapy, concentrating on its potential to transform cancer therapy radically.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"92157247","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Update of Diagnosis and Targeted Therapy for ALK⁺ Inflammation Myofibroblastic Tumor. ALK+炎症性肌纤维母细胞瘤的诊断和靶向治疗进展。

IF 4.3 2区医学

Current Treatment Options in Oncology Pub Date : 2023-12-01 Epub Date: 2023-11-08 DOI: 10.1007/s11864-023-01144-6

Qi-An Wang, Huan-Wu Chen, Ren-Chin Wu, Chiao-En Wu

{"title":"Update of Diagnosis and Targeted Therapy for ALK+ Inflammation Myofibroblastic Tumor.","authors":"Qi-An Wang, Huan-Wu Chen, Ren-Chin Wu, Chiao-En Wu","doi":"10.1007/s11864-023-01144-6","DOIUrl":"10.1007/s11864-023-01144-6","url":null,"abstract":"OPINION STATEMENT: Inflammatory myofibroblastic tumor (IMT), characterized by intermediate malignancy and a propensity for recurrence, has presented a formidable clinical challenge in diagnosis and treatment. Its pathological characteristics may resemble other neoplasms or reactive lesions, and the treatment was limited, taking chemotherapies as the only option for those inoperable. However, discovering anaplastic lymphoma kinase (ALK) protein expression in approximately 50% of IMT cases has shed light on a new diagnostic approach and application of targeted therapies. With the previous success of combating ALK+ non-small-cell lung cancers with ALK tyrosine kinase inhibitors (TKIs), crizotinib, a first-generation ALK-TKI, was officially approved by the U.S. Food and Drug Administration in 2020, to treat unresectable ALK+ IMT. After the approval of crizotinib, other ALK-TKIs, such as ceritinib, alectinib, brigatinib, and lorlatinib, have proven their efficacy on ALK+ IMT with sporadic case reports. The sequential treatments of targeted therapies in may provide the insight into the choice of ALK-TKIs in different lines of treatment for unresectable ALK+ IMT.","PeriodicalId":50600,"journal":{"name":"Current Treatment Options in Oncology","volume":null,"pages":null},"PeriodicalIF":4.3,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10781869/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71488385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0